Imagine a world where we conquer cancer and genetic diseases. At NTrans Technologies, we solve key challenges in cell and gene therapy: Delivering life-changing therapies to the right cells and tissues. We leverage nature’s own mechanisms for cellular uptake to ensure efficient and safe therapeutic delivery. Welcome to the next frontier of medicine. Our proprietary platform is GMP-ready and sets a new standard in cell and gene therapy. We use a non-viral delivery system to harness macropinocytosis - a natural cellular uptake process - for precise and secure delivery of gene-editing technologies. The mission of NTrans Technologies is to become the leading non-viral delivery platform in cell and gene therapy. Please contact us at: info@ntranstechnologies.com
Looking for a particular NTrans Technologies BV employee's phone or email?
The NTrans Technologies BV annual revenue was $202000 in 2026.
Ester Weijers is the CEO of NTrans Technologies BV.
3 people are employed at NTrans Technologies BV.
NTrans Technologies BV is based in Leiden, South Holland.
The NAICS codes for NTrans Technologies BV are [541, 54171, 541713, 5417, 54].
The SIC codes for NTrans Technologies BV are [87, 873].